| Osco Pharmacy #0495 | |
| 180a Cambridge St, Burlington, Massachusetts 01803 | |
| (781) 221-0144 |
| Name | Osco Pharmacy #0495 |
|---|---|
| Organization Name | Shaws Supermarkets Inc |
| Location | 180a Cambridge St, Burlington, Massachusetts 01803 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (781) 221-0144 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Emergent BioSolutions announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised a contract option to further advance the development of PreviThrax (Recombinant Protective Antigen Anthrax Vaccine, Purified), the company's novel rPA anthrax vaccine candidate.
Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.
PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.
Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.
› Verified 8 days ago
| NPI Number | 1275589707 |
| Organization Name | SHAWS SUPERMARKETS INC |
| Doing Business As | OSCO PHARMACY #0495 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 180a Cambridge St, Burlington, MA 01803 |
| Phone Number | 781-221-0144 |
News Archive
Emergent BioSolutions announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised a contract option to further advance the development of PreviThrax (Recombinant Protective Antigen Anthrax Vaccine, Purified), the company's novel rPA anthrax vaccine candidate.
Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.
PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.
Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.
› Verified 8 days ago
News Archive
Emergent BioSolutions announced today that, after completion of an inter-agency In Process Review, the Biomedical Advanced Research Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) has exercised a contract option to further advance the development of PreviThrax (Recombinant Protective Antigen Anthrax Vaccine, Purified), the company's novel rPA anthrax vaccine candidate.
Edison Pharmaceuticals today announced the initiation of a phase 2 study entitled "A Phase 2 Safety and Efficacy Study of EPI-743 (Vincerinone™) in Children with Pearson Syndrome." The Investigative New Drug application (IND) was approved by the Food and Drug Administration, Office of Hematology and Oncology Products.
PTC Therapeutics, Inc., the SMA Foundation, and Roche, announced today that their joint research program in Spinal Muscular Atrophy has entered the first stage of clinical development aiming to assess safety and tolerability of an oral compound in healthy volunteers.
Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.
› Verified 8 days ago
Cvs Pharmacy #05939 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 242 Cambridge St, Burlington, Massachusetts 01803 Phone: (781) 272-4146 | |
Cvs Pharmacy #01023 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 34 Cambridge St, Burlington, Massachusetts 01803 Phone: (781) 273-3645 | |
Wegmans Pharmacy #059 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 53 3rd Ave, Burlington, Massachusetts 01803 Phone: (781) 418-0745 | |
Osco Pharmacy #0495 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 180a Cambridge St, Burlington, Massachusetts 01803 Phone: (781) 221-0144 | |
Nordstrom Type: Prosthetic/Orthotic Supplier Location: 75 Middlesex Tpke, Burlington, Massachusetts 01803 Phone: (781) 345-7800 |